CL2016002361A1 - Compuestos derivados de azabenzofurano; composición farmacéutica, y su uso como inhibidores de la función de la proteína ns5b del hcv para el tratamiento de la hepatitis c. - Google Patents

Compuestos derivados de azabenzofurano; composición farmacéutica, y su uso como inhibidores de la función de la proteína ns5b del hcv para el tratamiento de la hepatitis c.

Info

Publication number
CL2016002361A1
CL2016002361A1 CL2016002361A CL2016002361A CL2016002361A1 CL 2016002361 A1 CL2016002361 A1 CL 2016002361A1 CL 2016002361 A CL2016002361 A CL 2016002361A CL 2016002361 A CL2016002361 A CL 2016002361A CL 2016002361 A1 CL2016002361 A1 CL 2016002361A1
Authority
CL
Chile
Prior art keywords
azabenzofuran
hepatitis
inhibitors
treatment
function
Prior art date
Application number
CL2016002361A
Other languages
English (en)
Inventor
Tao Wang
Kyle J Eastman
Zhongxing Zhang
Kyle E Parcella
Zhiwei Yin
John F Kadow
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CL2016002361A1 publication Critical patent/CL2016002361A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

COMPUESTOS DERIVADOS DE AZABENZOFURANO; COMPOSICIÓN FARMACÉUTICA, Y SU USO COMO INHIBIDORES DE LA FUNCIÓN DE LA PROTEÍNA NS5B DEL HCV PARA EL TRATAMIENTO DE LA HEPATITIS C.
CL2016002361A 2014-03-21 2016-09-20 Compuestos derivados de azabenzofurano; composición farmacéutica, y su uso como inhibidores de la función de la proteína ns5b del hcv para el tratamiento de la hepatitis c. CL2016002361A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461968763P 2014-03-21 2014-03-21

Publications (1)

Publication Number Publication Date
CL2016002361A1 true CL2016002361A1 (es) 2017-04-21

Family

ID=52808191

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002361A CL2016002361A1 (es) 2014-03-21 2016-09-20 Compuestos derivados de azabenzofurano; composición farmacéutica, y su uso como inhibidores de la función de la proteína ns5b del hcv para el tratamiento de la hepatitis c.

Country Status (18)

Country Link
US (1) US9249152B2 (es)
EP (1) EP3119785B1 (es)
JP (1) JP2017509700A (es)
KR (1) KR20160126085A (es)
CN (1) CN106459070A (es)
AR (1) AR099820A1 (es)
AU (1) AU2015231139A1 (es)
CA (1) CA2943526A1 (es)
CL (1) CL2016002361A1 (es)
EA (1) EA201691777A1 (es)
ES (1) ES2688554T3 (es)
IL (1) IL247830A0 (es)
MX (1) MX2016012104A (es)
PE (1) PE20161224A1 (es)
SG (1) SG11201607750PA (es)
TW (1) TW201620914A (es)
WO (1) WO2015143255A1 (es)
ZA (1) ZA201606478B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015143256A1 (en) * 2014-03-21 2015-09-24 Bristol-Myers Squibb Company Cyanoamino (aza)benzofuran compounds for the treatment of hepatitis c
KR20180086247A (ko) * 2015-12-07 2018-07-30 플렉시콘 인코퍼레이티드 키나제 조절을 위한 화합물 및 방법과 이들에 대한 징후

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041201A2 (en) 2002-11-01 2004-05-21 Viropharma Incorporated Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
EP2245023B1 (en) 2008-02-14 2011-12-28 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
US8048887B2 (en) * 2008-09-11 2011-11-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7994171B2 (en) * 2008-09-11 2011-08-09 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8198449B2 (en) * 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2545050B1 (en) * 2010-03-10 2014-08-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
NZ609564A (en) 2010-10-26 2015-06-26 Presidio Pharmaceuticals Inc Inhibitors of hepatitis c virus

Also Published As

Publication number Publication date
JP2017509700A (ja) 2017-04-06
ZA201606478B (en) 2018-05-30
TW201620914A (zh) 2016-06-16
EP3119785A1 (en) 2017-01-25
IL247830A0 (en) 2016-11-30
EP3119785B1 (en) 2018-08-15
WO2015143255A1 (en) 2015-09-24
MX2016012104A (es) 2016-12-09
KR20160126085A (ko) 2016-11-01
ES2688554T3 (es) 2018-11-05
PE20161224A1 (es) 2016-11-12
US20150266886A1 (en) 2015-09-24
SG11201607750PA (en) 2016-10-28
US9249152B2 (en) 2016-02-02
CA2943526A1 (en) 2015-09-24
AR099820A1 (es) 2016-08-17
AU2015231139A1 (en) 2016-11-03
CN106459070A (zh) 2017-02-22
EA201691777A1 (ru) 2016-12-30

Similar Documents

Publication Publication Date Title
CL2016000493A1 (es) Inhibidores de polimerasa hcv.
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2016002179A1 (es) Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b.
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
CL2016003398A1 (es) Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo.
CO2017004736A2 (es) Péptidos macrociclicos útiles como inmunomoduladores
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
CL2016002269A1 (es) Moduladores alostéricos del núcleo proteico de la hepatitis b.
CL2016000952A1 (es) Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
EA201790630A1 (ru) Способы получения рибозидов
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
CL2016001840A1 (es) Compuestos derivados de pirimidinas fusionadas como inhibidores del complejo p97; composicion farmaceutica y uso en el tratamiento del cancer.
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
CL2015002897A1 (es) Inhibidores de bace1
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
EA201692358A1 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
CL2016002482A1 (es) Compuestos de azol sustituidos con amida como inhibidores de tnks1 y/o tnks2.